Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DCVC inhibits pathogen-stimulated TNF-α in human extra placental membranes in vitro.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 275.00 | |
5 mg | 5 days | $ 347.00 | |
10 mg | 5 days | $ 541.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 382.00 |
Description | DCVC inhibits pathogen-stimulated TNF-α in human extra placental membranes in vitro. |
In vitro | In vitro, DCVC inhibits pathogen stimulated cytokine release from tissue punch cultures. DCVC (5-50 μM) significantly inhibits LTA-, LPS-, and GBS-stimulated cytokine release from tissue cultures as early as 4 h (P ≤ 0.05). In contrast, TCA (up to 500 μM) does not inhibit LTA-stimulated cytokine release from tissue punches. DCVC effects on LTA-stimulated and LPS-stimulated TNF-α release from tissue punch cultures of extraplacental membranes. DCVC effects on GBS-stimulated release of pro-inflammatory cytokines from extraplacental membranes in transwell cultures. |
Molecular Weight | 216.09 |
Formula | C5H7Cl2NO2S |
CAS No. | 13419-46-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 23 mg/mL (106.44 mM)
H2O: 1.034 mg/mL (4.79 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DCVC 13419-46-0 inhibitor inhibit